Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print? bySrinathMay 13, 2026